Search clinical trials for: Placebo solution for risankizumab

Total 7236 results

AbbVie

Completed

Risankizumab Therapy Versus Placebo for Subjects With Psoriasis in the Russian Federation (IMMPRESS)

Psoriasis

Russian Federation
AbbVie

Completed

A Study to Assess Safety and Efficacy of Risankizumab Using a New Formulation in Participants With Moderate to Severe Plaque Psoriasis

Psoriasis

United States, Puerto Rico
AbbVie

Active, not recruiting

A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn's Disease

Crohn's Disease

United States, Argentina, Australia, Austria, Belarus, Belgium, Bosnia and Herzegovina, Bulgaria, Canada, Chile, China, Colombia, Croatia, Czechia, Denmark, Egypt, Estonia, France, Germany, Greece, Hong Kong, Ireland, Israel, Italy, Japan, Korea, Republic... and more
AbbVie
Boehringer Ingelheim

Completed

BI 655066 (Risankizumab) Proof of Concept Dose Finding Study in Ankylosing Spondylitis (AS)

Ankylosing Spondylitis (AS)
AbbVie

Completed

A Study of the Efficacy and Safety of Risankizumab in Participants With Moderately to Severely Active Crohn's Disease

Crohn's Disease

United States, Argentina, Australia, Austria, Belarus, Belgium, Bosnia and Herzegovina, Brazil, Bulgaria, Canada, Chile, China, Colombia, Croatia, Czechia, Estonia, Germany, Greece, Hong Kong, Ireland, Israel, Italy, Japan, Korea, Republic... and more
AbbVie

Completed

A Multicenter, Randomized, Double-Blind, Placebo Controlled Induction Study to Evaluate the Efficacy and Safety of Risankizumab in Participants With Moderately to Severely Active Ulcerative Colitis

Ulcerative Colitis (UC)

United States, Argentina, Austria, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Croatia, Czechia, Denmark, Egypt, France, Germany, Greece, Israel, Italy, Japan, Korea, Republic of, Latvia, Lithuania, Malaysia, Mexico, Nether... and more
AbbVie

Recruiting

Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis (UnlIMMited)

Scalp Psoriasis | Genital Psoriasis

United States
AbbVie

Completed

Study of Subcutaneous (Injected Under the Skin) Risankizumab to Assess Change in Disease Symptoms in Adult Participants With Moderate to Severe Plaque Psoriasis With Palmoplantar Involvement (IMMprint)

Psoriasis

United States, Canada, Puerto Rico, Spain
AbbVie

Completed

A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Moderately to Severely Active Crohn's Disease Who Failed Prior Biologic Treatment

Crohn's Disease

United States, Argentina, Australia, Austria, Belarus, Belgium, Bosnia and Herzegovina, Bulgaria, Canada, Chile, China, Colombia, Croatia, Czechia, Denmark, Egypt, Estonia, France, Germany, Greece, Ireland, Israel, Italy, Korea, Republic... and more
AbbVie

Recruiting

A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn's Disease.

Crohn's Disease

United States, Canada, Israel, Taiwan, Japan, Korea, Republic of
AbbVie

Completed

A Global Study Comparing Risankizumab to Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa (DETERMINED 1)

Hidradenitis Suppurativa

United States, Australia, Canada, France, Germany, Japan, Netherlands, Spain
AbbVie
Boehringer Ingelheim

Completed

BI 655066 Versus Placebo & Active Comparator (Ustekinumab) in Patients With Moderate to Severe Chronic Plaque Psoriasis

Psoriasis
AbbVie
Boehringer Ingelheim

Completed

BI 655066 (Risankizumab) Compared to Placebo in Japanese Patients With Moderate to Severe Chronic Plaque Psoriasis

Psoriasis
AbbVie

Active, not recruiting

A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Ulcerative Colitis

Ulcerative Colitis (UC)

United States, Argentina, Austria, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Croatia, Czechia, Denmark, Egypt, France, Germany, Greece, Israel, Italy, Japan, Korea, Republic of, Latvia, Lithuania, Mexico, Netherlands, New... and more
AbbVie
Boehringer Ingelheim

Completed

BI 655066/ABBV-066/Risankizumab Compared to Placebo in Patients With Active Psoriatic Arthritis

Arthritis, Psoriatic
AbbVie
Boehringer Ingelheim

Completed

BI 655066 (Risankizumab) Compared to Placebo and Active Comparator (Ustekinumab) in Patients With Moderate to Severe Chronic Plaque Psoriasis

Psoriasis
AbbVie
Boehringer Ingelheim

Completed

BI 655066/ABBV-066 (Risankizumab) Compared to Active Comparator (Adalimumab) in Patients With Moderate to Severe Chronic Plaque Psoriasis

Psoriasis
Institut de Recherches Internationales Servier
ADIR, a Servier Group company

Completed

Efficacy and Safety of S95011 in Primary Sjögren's Syndrome Patients

Primary Sjögren's Syndrome

United States, France, United Kingdom, Australia, Germany, Hungary, Spain
AbbVie

Completed

Study of Subcutaneous Risankizumab Injection to Assess Change in Palmoplantar Pustulosis Area and Severity Index [PPPASI] in Adult Japanese Participants With Palmoplantar Pustulosis

Palmoplantar Pustulosis (PPP)

Japan
AbbVie

Completed

A Study in Healthy Japanese and Caucasian Subjects to Assess the Pharmacokinetics, Safety and Tolerability of Risankizumab

Healthy Volunteers

United States
Boehringer Ingelheim

Recruiting

A Study to Test Whether Spesolimab Helps People With a Skin Disease Called Netherton Syndrome

Netherton Syndrome

Belgium, United Kingdom, Australia, Germany, China, Malaysia, Japan, France, United States, Israel, Bulgaria, Italy, Switzerland, Austria, Netherlands, Portugal
AbbVie

Completed

A Study to Evaluate Risankizumab in Adults and Adolescents With Moderate to Severe Atopic Dermatitis

Dermatitis

United States, Australia, Canada, Japan, Puerto Rico
AbbVie
Boehringer Ingelheim

Completed

BI 655066 / ABBV-066 (Risankizumab) in Moderate to Severe Plaque Psoriasis With Randomized Withdrawal and Re-treatment

Psoriasis
GlaxoSmithKline

Completed

Study to Investigate the Pharmacokinetics (PK), Safety and Tolerability of Retosiban in Healthy Japanese Women

Obstetric Labour, Premature

United States
Artery Therapeutics, Inc.
National Institute on Aging (NIA)

Recruiting

Safety and Pharmacokinetics of Single Ascending Doses and Multiple Ascending Doses of CS6253 in Healthy Volunteers

Alzheimer's Disease

Spain
Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories...
Attikon Hospital

Terminated

Triiodothyronine for the Treatment of Critically Ill Patients With COVID-19 Infection (Thy-Support)

Covid-19 | Pulmonary Infection

Greece
AbbVie

Active, not recruiting

A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) (KEEPsAKE2)

Psoriatic Arthritis (PsA)

United States, Argentina, Australia, Belgium, Brazil, Canada, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Israel, Italy, Netherlands, New Zealand, Poland, Portugal, Puerto Rico, Singapore, South Africa, Spain, Sweden, United...
Aerami Therapeutics

Completed

Safety, Tolerability, & Pharmacokinetics Study of Single & Multiple Inhaled Doses of Imatinib Inhalation Solution

Pulmonary Arterial Hypertension

Australia
Boehringer Ingelheim

Completed

Safety, Tolerability and Pharmacokinetics of BEA 2180 BR in Healthy Male Volunteers

Healthy
10xBio, LLC
Therapeutics, Inc.

Active, not recruiting

Safety and Efficacy Study of 10XB-101 in Adults With Bilateral Flank Adiposity

Subcutaneous Fat Disorder

United States
Guard Therapeutics AB

Completed

A Study to Evaluate RMC-035 in Subjects Undergoing Cardiac Surgery

Acute Kidney Injury (AKI)

Germany
University of Cologne

Recruiting

Clinical Trial to Evaluate Efficacy and Safety of Dupilumab in Localized Scleroderma (DupiMorph)

Localized Scleroderma

Germany
Lianyungang Kanion Group, Ltd.

Completed

JINZHEN for Treatment of Mild to Moderate COVID-19

COVID-19

United States
GlaxoSmithKline

Completed

A Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability, Immunogenicity, and Pharmacodynamics (PD) of GSK2800528 in Healthy Subjects.

Psoriasis

United Kingdom
AbbVie
Boehringer Ingelheim

Completed

Efficacy and Safety of BI 655066/ABBV-066 (Risankizumab) in Patients With Severe Persistent Asthma

Asthma

United States, Korea, Republic of, Belgium, Taiwan, Canada, Germany, United Kingdom, France, Netherlands, Poland
AbbVie

Completed

A Study to Assess Usability of Risankizumab Autoinjector Combination Product in Participants With Moderate to Severe Plaque Psoriasis

Psoriasis

United States
argenx

Not yet recruiting

A Study to Evaluate Safety and Efficacy of Empasiprubart in Adults With Dermatomyositis (empacific)

Myositis | Dermatomyositis
Ferring Pharmaceuticals

Completed

Comparison of MENOPUR Liquid and Powder in Women Undergoing Assisted Reproductive Technology (ART) (CLARA)

Infertility

United States
AbbVie
Boehringer Ingelheim

Completed

Efficacy, Safety and Pharmacokinetics of BI 655066/ABBV-066 (Risankizumab) in Patients With Active, Moderate-to-severe Crohn's Disease.

Crohn Disease
Sirnaomics

Recruiting

Single Ascending Dose of FXI-GalNAc-siRNA in Healthy Subjects

FXI

United States, Canada
Apeptico Forschung und Entwicklung GmbH

Recruiting

Safety and Preliminary Efficacy of Sequential Multiple Ascending Doses of Solnatide to Treat Pulmonary Permeability Oedema in Patients With Moderate-to-severe ARDS

ARDS

Austria, Germany
Neupharma Srl
Sintesi Research Srl; Pari Pharma GmbH; Aptuit

Completed

Open-label, Dose-escalation Study to Evaluate the Pharmacokinetics of Inhaled Teicoplanin in Cystic Fibrosis Patients

Cystic Fibrosis

Italy
Mayo Clinic

Recruiting

Serial Amnioinfusions as Regenerative Therapy for Pulmonary Hypoplasia

Lower Urinary Tract Obstructive Syndrome | Renal Failure Congenital | Congenital Renal Anomaly Nos | Renal Agenesis and Dysgenesis

United States
PharmaMar

Completed

Clinical Study of PM01183 in Patients With Acute Leukemia or Relapsed/Refractory Myelodysplastic Syndrome

Acute Leukemia

United States
10xBio, LLC

Active, not recruiting

A Safety and Tolerability Study of 10XB-101 Injection in Adult Subjects With Submental Fat

Submental Fat

United States
Boehringer Ingelheim

Completed

Safety and Tolerability of BI 638683 After Single Rising Oral Doses in Healthy Male Subjects

Healthy

Germany
Boehringer Ingelheim

Completed

Single Rising Oral Doses of BI 207127 NA as Powder in the Bottle in Healthy Male Subjects

Healthy
AbbVie

Active, not recruiting

A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy (KEEPsAKE 1)

Psoriatic Arthritis

United States, Argentina, Australia, Belgium, Bosnia and Herzegovina, Brazil, Bulgaria, Canada, Chile, Croatia, Czechia, Denmark, Estonia, Finland, Germany, Greece, Israel, Italy, Korea, Republic of, Latvia, Lithuania, Malaysia, Mexico and more
Bayer

Completed

Study Comparing PEG 3350 Laxative to Placebo in the Treatment of Occasional Constipation (Study CL2007-12)(P08216)

Constipation
Geisinger Clinic

Terminated

Effect of Subcutaneous Semaglutide on Kidney Transplant Candidacy (RAISE-KT)

Obesity | Diabetic Kidney Disease | Type 2 Diabetes Mellitus in Obese | CKD | Severe Obesity

United States

3

Subscribe